TD Cowen Raises WST Price Target to $420

TD Cowen has reiterated its Buy rating for West Pharmaceutical Services with a new price target of $420, a 10.33% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:18 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

TD Cowen raised its price target on West Pharmaceutical Services, Inc. ($WST) to $420 from $410 on October 13, 2026, and rates the stock "Buy".

Since the rating, $WST is up 3.3% to date (from the $371.82 close on Oct 13, 2026).

WST West Pharmaceutical Services, Inc.

$384.02 +39.26% year to date

Daily close · Oct 16, 2026

Key Points

On October 13, 2026, TD Cowen reiterated its Buy rating on West Pharmaceutical Services, Inc. with a new price target of $420, up from $410.
TD Cowen's $420 price target implies 10.33% upside from West Pharmaceutical Services, Inc.'s ($WST) current $380.68 share price.
The stock recently traded around $380.68, which is about 9.4% below the new target price.
West Pharmaceutical has a strong financial performance, with a trailing twelve-month revenue of approximately $3.33 billion and a net margin of 17.0%.

Get $WST trade alerts by text

We text you when insiders, Congress or big funds trade $WST. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated West Pharmaceutical Services, Inc. alert may contain errors. Disclosures

TD Cowen has reiterated its Buy rating on West Pharmaceutical Services, Inc. (NYSE: WST) on October 13, 2026, setting a new price target of $420, up from the previous target of $410. This change comes as the stock recently traded at $380.68, which is about 9.4% below the new target price.

Other Institutional Activity in West Pharmaceutical Services

Several institutional investors have adjusted their positions in West Pharmaceutical recently. FMR, LLC increased its holdings by 2,325,055 shares, ending with 3,574,816 shares worth about $1.37 billion. State Street Corporation added 55,005 shares, bringing its total to 3,348,698 shares valued at approximately $1.29 billion. On the other hand, Blackrock Inc. reduced its stake by 184,582 shares, holding 6,651,784 shares worth about $2.55 billion. Vanguard Capital Management LLC and Vanguard Portfolio Management LLC also trimmed their positions, with reductions of 70,251 and 78,195 shares, respectively.

West Pharmaceutical Services, Inc. Stock Up 5.1%

The stock of West Pharmaceutical is currently trading below the new price target of $420, which may indicate potential upside if the market responds positively to the company's upcoming earnings report. The recent price of $380.68 is relevant as it is situated below the analyst's target, suggesting that investors may see value in the stock if it approaches that target.

12-month forecast

$WST price target

West Pharmaceutical Services, Inc. daily closes and this analyst's $420 target. Not advice.

Recent Earnings

West Pharmaceutical reported a trailing twelve-month revenue of approximately $3.33 billion, showing a year-over-year revenue growth of 13.8%. The company has a net margin of 17.0% and a return on equity (ROE) of 19.1%. The next earnings report is scheduled for October 22, 2026.

Insider Buying and Selling at West Pharmaceutical Services, Inc.

Recent insider transactions have shown some activity at West Pharmaceutical. Annette F Favorite, an officer, sold 2,817 shares on April 27, 2026, at an average price of $305.20, totaling about $859,753. She also sold 8,135 shares on September 8, 2026, for approximately $2.77 million at an average price of $340.81. Additionally, she sold another 7,524 shares on September 15, 2026, with an undisclosed price, valued at about $2.67 million. Chad Winters, another officer, sold 896 shares on April 27, 2026, for about $269,399 at an average price of $300.67.

Analysts Set New Price Targets

On October 13, 2026, TD Cowen maintained its Buy rating on West Pharmaceutical Services with a target price of $420, up from $410. Other firms have also shown positive sentiment; Citigroup maintained a Buy rating with a target of $412 on August 3, 2026, and UBS maintained a Buy with a target of $415 on September 9, 2026. The consensus among analysts indicates a generally bullish outlook for the stock.

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. designs and manufactures systems for delivering injectable drugs and healthcare products. The company operates in both Proprietary Products and Contract-Manufactured Products segments and serves clients across the Americas, Europe, the Middle East, Africa, and Asia Pacific. With a focus on innovation in medical instruments, it plays a vital role in the healthcare sector.

Bottom Line

Investors should keep an eye on the upcoming earnings report on October 22, 2026, as it could influence future analyst ratings and stock performance. The recent reiteration of the Buy rating by TD Cowen suggests confidence in the company's prospects, despite the current trading price being below the new target.